Ashland is making great progress as we transform into a leaner, more cost-competitive and growth-oriented specialty chemicals company, and the board is actively engaged in overseeing Ashland’s transformation.
Importantly, Ashland’s fiscal 2018 financial results demonstrate that the company’s plan is working. Ashland is far exceeding the financial commitments outlined at its Investor Day in May 2017, and the market recognizes Ashland’s progress to deliver enhanced value with Ashland’s stock price increasing 28% in 2018. Looking ahead, the board and management team are confident that Ashland will continue delivering stronger growth and enhanced shareholder value.
At Ashland’s upcoming Annual Meeting of Stockholders, you will have an important decision regarding which directors are most qualified to oversee Ashland through its transformation.
Ashland has a diverse, experienced, refreshed board that brings extensive experience in areas critical to Ashland’s business, including in chemicals, executive leadership, accounting and finance, operations, global and international business, experience serving on the boards of public companies and experience in research and development, science and technology.
We urge Ashland shareholders to vote “FOR” all 11 of Ashland’s qualified and experienced director nominees – Brendan M. Cummins, William G. Dempsey, Jay V. Ihlenfeld, Susan L. Main, Jerome A. Peribere, Craig A. Rogerson, Mark C. Rohr, Janice J. Teal, Michael J. Ward, Kathleen Wilson-Thompson and William A. Wulfsohn – on the BLUE proxy card today.